iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/39261421/
Endocrinological Treatment Targets for Depressive Disorder - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:1456:3-25.
doi: 10.1007/978-981-97-4402-2_1.

Endocrinological Treatment Targets for Depressive Disorder

Seoyoung Yoon  1 , Yong-Ku Kim  2
Affiliations
Review

Endocrinological Treatment Targets for Depressive Disorder

Seoyoung Yoon et al. Adv Exp Med Biol. 2024.

Abstract

Depressive disorder exhibits heterogeneity in clinical presentation, progression, and treatment outcomes. While conventional antidepressants based on the monoamine hypothesis benefit many patients, a significant proportion remains unresponsive or fails to fully recover. An individualized integrative treatment approach, considering diverse pathophysiologies, holds promise for these individuals. The endocrine system, governing physiological regulation and organ homeostasis, plays a pivotal role in central nervous system functions. Dysregulations in endocrine system are major cause of depressive disorder due to other medical conditions. Subtle endocrine abnormalities, such as subclinical hypothyroidism, are associated with depression. Conversely, depressive disorder correlates with endocrine-related biomarkers. Fluctuations in sex hormone levels related to female reproduction, elevate depression risk in susceptible subjects. Consequently, extensive research has explored treatment strategies involving the endocrine system. Treatment guidelines recommend tri-iodothyronine augmentation for resistant depression, while allopregnanolone analogs have gained approval for postpartum depression, with ongoing investigations for broader depressive disorders. This book chapter will introduce the relationship between the endocrine system and depressive disorders, presenting clinical findings on neuroendocrinological treatments for depression.

Keywords: Depressive disorder; Glucocorticoid; Integrative treatment; Neurosteroid; Thyroid.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Alemany M (2022) The roles of androgens in humans: biology, metabolic regulation and health. Int J Mol Sci 23(19):11952 - PubMed - PMC - DOI
    1. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP et al (2001) Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 158(10):1617–1622 - PubMed - DOI
    1. Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT (2014) Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry 26(1):19–32 - PubMed
    1. American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders. Fifth edition, text revision ed. American Psychiatric Association, Washington, DC - DOI
    1. Anacker C, Zunszain PA, Carvalho LA, Pariante CM (2011) The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 36(3):415–425 - PubMed - PMC - DOI

MeSH terms

LinkOut - more resources